METTL7A: A Potential Drug Target for Cancer (G25840)

Target Name: METTL7A

NCBI ID: G25840

METTL7A

METTL7A: A Potential Drug Target for Cancer

METTL7A, also known as DKFZp586A0522, is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The METTL7A gene is located on chromosome 16 and encodes a protein known as METTL7A, which plays a role in the development and progression of cancer.

Recent studies have shown that METTL7A is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, the expression of METTL7A has been associated with cancer cell sensitivity to chemotherapy and poor prognosis.

One of the main reasons for the potential drug target status of METTL7A is its role in the development of resistance to chemotherapy. Cancer cells can evolve to become resistant to the effects of chemotherapy by acquiring mechanisms to avoid or bypass the drug's therapeutic effects. METTL7A has been shown to be involved in the development of resistance in various cancer types, which could make it an attractive target for cancer chemotherapy.

Another potential drug target for METTL7A is its role in cell signaling. METTL7A is a transcription factor that has been shown to regulate various cellular processes, including cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). aberrant METTL7A expression has been linked to the development and progression of various diseases, including cancer.

In addition to its potential as a drug target, METTL7A has also been identified as a potential biomarker for cancer. The expression of METTL7A has been shown to be associated with the poor prognosis of cancer patients. Additionally, METTL7A has been shown to be expressed in various types of cancer, including the most aggressive forms of cancer, which could make it an attractive biomarker for cancer diagnosis and prognosis.

Overall, METTL7A is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases, including cancer. Further research is needed to fully understand the role of METTL7A in cancer development and progression.

Protein Name: Methyltransferase Like 7A

Functions: N(6)-adenine-methyltransferase able to methylate both DNA and long non-coding RNAs. Methylates adenosine residues at the N6 position of some long non-coding RNAs (lncRNAs) (PubMed:34980213). DNA methylation by TMT1A promote osteogenic and odontogenic differentiation by upregulating expression of genes that promote differentiation and survival (PubMed:34226523, PubMed:34790668). Recruits cellular proteins to the lipid droplet for the formation of functional organelles (PubMed:19773358). Acts also as an oncogene in multiple myeloma (PubMed:34790668)

The "METTL7A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL7A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets